IMA · ImageneBio Inc. Common Stock
View on chartInsiders & Stakes
| FORMELA JEAN FRANCOIS Director | ▼ Sell | Open Market | 1,241,935 Shares held | 12/14/2021 | View profile |
| Atlas Venture Fund XI, L.P. 10% Owner | ▼ Sell | Open Market | 1,241,935 Shares held | 12/14/2021 | View profile |
| Jonathan Jian Wang | ▲ Buy | Grant | 971,173 Shares held | 7/25/2025 | View profile |
| Kristin Yarema Chief Executive Officer | ▲ Buy | Grant | 493,705 Shares held | 8/14/2026 | View profile |
| Otello Stampacchia | ▲ Buy | Open Market | 454,982 Shares held | 7/25/2025 | View profile |
| ORBIMED ADVISORS LLC Director | ▲ Buy | Grant | 287,885 Shares held | 7/25/2025 | View profile |
| David P. Bonita Director | ▲ Buy | Open Market | 287,885 Shares held | 7/25/2025 | View profile |
| Yanina Grant-Huerta Chief Financial Officer | ▲ Buy | Grant | 104,000 Shares held | 8/14/2026 | View profile |
| Tessier Maude Chief Business Officer | ▲ Buy | Option Exercise | 100,578 Shares held | 1/18/2022 | View profile |
| Robert B. Lally Principal Accounting Officer | ▼ Sell | Open Market | 55,582 Shares held | 7/17/2026 | View profile |
| Zhang Xiaoyan Michelle Chief Scientific Officer | ▼ Sell | Open Market | 44,475 Shares held | 1/11/2022 | View profile |
| Erin Butler Principal Accounting Officer | ▲ Buy | Grant | 25,551 Shares held | 12/30/2025 | View profile |
| Joseph P. Slattery Director | ▲ Buy | Open Market | 16,000 Shares held | 12/24/2025 | View profile |
| Stephen Hui Wang | ▲ Buy | Grant | 12,535 Shares held | 7/25/2025 | View profile |
| Jotin Marango Chief Financial Officer | ▼ Sell | Tax Withholding | 11,146 Shares held | 7/28/2025 | View profile |
Transaction History
| Yanina Grant-Huerta | ▲ Buy | Grant | 65,000 | $0 | 8/14/2026 |
| Yanina Grant-Huerta | ▲ Buy | Grant | 39,000 | $0 | 8/14/2026 |
| Kristin Yarema | ▲ Buy | Grant | 254,800 | $0 | 8/14/2026 |
| Kristin Yarema | ▲ Buy | Option Exercise | 38,376 | $0 | 7/25/2026 |
| Kristin Yarema | ▼ Sell | Other | 115,129 | $0 | 7/25/2026 |
| Robert B. Lally | ▼ Sell | Open Market | 1,525 | $8K | 7/17/2026 |
| Robert B. Lally | ▼ Sell | Open Market | 1,671 | $9K | 7/16/2026 |
| Kristin Yarema | ▲ Buy | Grant | 85,400 | $0 | 3/16/2026 |
| Erin Butler | ▲ Buy | Grant | 22,500 | $0 | 12/30/2025 |
| Joseph P. Slattery | ▲ Buy | Open Market | 16,000 | $96K | 12/24/2025 |
| Jotin Marango | ▲ Buy | Grant | 15,776 | — | 7/28/2025 |
| Jotin Marango | ▼ Sell | Tax Withholding | 4,630 | $79K | 7/28/2025 |
| David P. Bonita | ▲ Buy | Option Exercise | 379 | — | 7/25/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Grant | 83,611 | $208K | 7/25/2025 |
| David P. Bonita | ▲ Buy | Open Market | 83,611 | $2.5M | 7/25/2025 |
| Otello Stampacchia | ▲ Buy | Option Exercise | 379 | — | 7/25/2025 |
| Otello Stampacchia | ▲ Buy | Open Market | 267,556 | $8.0M | 7/25/2025 |
| Erin Butler | ▲ Buy | Grant | 3,051 | — | 7/25/2025 |
| Stephen Hui Wang | ▲ Buy | Grant | 188,042 | — | 7/25/2025 |
| Stephen Hui Wang | ▲ Buy | Grant | 50,144 | — | 7/25/2025 |
| Stephen Hui Wang | ▲ Buy | Grant | 12,535 | — | 7/25/2025 |
| Jonathan Jian Wang | ▲ Buy | Grant | 143,832 | — | 7/25/2025 |
| Jonathan Jian Wang | ▲ Buy | Grant | 971,173 | — | 7/25/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Grant | 153,121 | — | 8/4/2023 |
| David P. Bonita | ▲ Buy | Grant | 153,121 | — | 8/4/2023 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 65,965 | $288K | 6/24/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 96,035 | $516K | 6/24/2022 |
| David P. Bonita | ▲ Buy | Open Market | 96,035 | $516K | 6/24/2022 |
| David P. Bonita | ▲ Buy | Open Market | 65,965 | $288K | 6/24/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 23,419 | $87K | 6/23/2022 |
| David P. Bonita | ▲ Buy | Open Market | 23,419 | $87K | 6/23/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 66,806 | $237K | 6/22/2022 |
| David P. Bonita | ▲ Buy | Open Market | 66,806 | $237K | 6/22/2022 |
| Tessier Maude | ▲ Buy | Option Exercise | 38,915 | $114K | 1/18/2022 |
| Tessier Maude | ▲ Buy | Option Exercise | 24,606 | $102K | 1/18/2022 |
| Tessier Maude | ▲ Buy | Option Exercise | 8,265 | $37K | 1/18/2022 |
| Zhang Xiaoyan Michelle | ▲ Buy | Option Exercise | 964 | $2K | 1/11/2022 |
| Zhang Xiaoyan Michelle | ▼ Sell | Open Market | 964 | $12K | 1/11/2022 |
| Zhang Xiaoyan Michelle | ▲ Buy | Option Exercise | 36 | $77 | 1/10/2022 |
| Zhang Xiaoyan Michelle | ▼ Sell | Open Market | 36 | $432 | 1/10/2022 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 5,959 | $83K | 12/14/2021 |
| FORMELA JEAN FRANCOIS | ▼ Sell | Open Market | 5,959 | $83K | 12/14/2021 |
| FORMELA JEAN FRANCOIS | ▼ Sell | Open Market | 8,330 | $122K | 12/13/2021 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 8,330 | $122K | 12/13/2021 |
| Zhang Xiaoyan Michelle | ▲ Buy | Option Exercise | 1,000 | $2K | 12/10/2021 |
| Zhang Xiaoyan Michelle | ▼ Sell | Open Market | 1,000 | $15K | 12/10/2021 |
| FORMELA JEAN FRANCOIS | ▼ Sell | Open Market | 11,989 | $180K | 12/10/2021 |
| Atlas Venture Fund XI, L.P. | ▼ Sell | Open Market | 11,989 | $180K | 12/10/2021 |
| FORMELA JEAN FRANCOIS | ▲ Buy | Open Market | 125,000 | $2.0M | 3/30/2021 |
| Atlas Venture Fund XI, L.P. | ▲ Buy | Open Market | 125,000 | $2.0M | 3/30/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule
ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.